AZD0780
Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with HeFH (AZURE-HeFH) (NCT07000136)
Study title/design: A Phase 3 Study to assess the effect of AZD0780 on LDL-C in patients with HeFH (AZURE-HeFH) (NCT07000136) Trial NCT07000136. Not yet recruiting. Estimated primary and study completion 26 March 2027. Aim To evaluate the efficacy and safety of AZD0780 in adults with HeFH…
read more »
Phase 3 study of AZD0780 on major adverse CV events in patients with a history of ASCVD events or at high risk of a first event (AZURE-Outcomes) (NCT07000357)
Study title/design: Phase 3 study of AZD0780 on major adverse CV events in patients with a history of ASCVD events or at high risk of a first event (AZURE-Outcomes) (NCT07000357) Trial NCT07000357. Not yet recruiting. Estimated primary and study completion 26 October 2029. Aim To…
read more »
Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with clinical ASCVD or at risk of a first ASCVD event (AZURE-LDL) (NCT07000123)
Study title/design: Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with clinical ASCVD or at risk of a first ASCVD event (AZURE-LDL) (NCT07000123) Trial NCT07000123. Not yet recruiting. Estimated primary and study completion 26 March 2027. Aim To evaluate the…
read more »
A study to assess the efficacy, safety and tolerability of different doses of AZD0780 in patients with dyslipidaemia (NCT06173570) (PURSUIT)
Study title/design: A study to assess the efficacy, safety and tolerability of different doses of AZD0780 in patients with dyslipidaemia (NCT06173570) (PURSUIT) Trial NCT06173570 (Completed 30 September 2024). Aim To measure the effect of different daily doses of AZD0780 on LDL-C levels and other lipid…
read more »
Phase 1 randomised, single-blind, placebo-controlled study of AZD0780 (NCT05384262)
Study title/design: Phase 1 randomised, single-blind, placebo-controlled study of AZD0780 (NCT05384262) Trial First-in-human single ascending and multiple dose study of AZD0780 (NCT05384262) (Completed). Aim To assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of AZD0780 as monotherapy, and in addition to standard of care (rosuvastatin)…
read more »
